A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers

Inclusion Criteria: * Caucasian * No previous/current history of infection, cerebrovascular, neurological, cardiovascular, endocrine, pulmonary, immunologic or metabolic disease or significant systemic disease, glucose intolerance, gout or hematological disorder * Normal 12-lead Electrocardiogram (ECG) * Systolic blood pressure \<140 mm Hg and diastolic blood pressure \<90 mm Hg * Non-smoker within 3 months prior to screening * Willing to abstain from alcohol during the study Exclusion Criteria: * Positive screen for illicit drug or alcohol consumption * Subject has hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or history of cancer (excluding completely excised squamous or basal cell carcinoma) * Positive tuberculin skin test or known history of tuberculosis infection * Known history of serious head injuries, seizures or eating disorders * Body Mass Index \<18.0 or \>30.0 * History of renal dysfunction, clinically significant creatinine or clinically significant abnormal liver function tests, hemoglobin \<130 g/L * Plasma donation ≥ 500 mL within 7 days prior to first dose of study drug, donation or whole blood loss 50-499 mL within 30 days or ≥ 499 mL within 56 days prior to first dose of study drug. * Drug or alcohol abuse within 1 year prior to study entry * Steroid injections within 12 weeks prior to first dose of study drug * Live vaccine within 7 days prior to first dose of study drug